Cardio Diagnostics shares surge 10.23% after-hours as new data shows PrecisionCHD detects INOCA/MINOCA with 90% accuracy at AHA conference.

Cardio Diagnostics Holdings (CDIO) surged 10.23% in after-hours trading following the announcement that its PrecisionCHD test demonstrated strong ability to detect INOCA and MINOCA, underdiagnosed heart conditions linked to high mortality. The company will present data at the American Heart Association Scientific Sessions showing the test’s epigenetic biomarkers achieved an area under the curve (AUC) of 0.90 in identifying these conditions, offering a noninvasive, scalable solution for personalized cardiovascular care. The findings, validated in a study of 267 patients and building on prior research, highlight the test’s potential to address a critical diagnostic gap, particularly for women and underserved populations. The event aligns with the stock’s upward movement, reflecting investor optimism about the test’s clinical and commercial implications.